Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation Study

This study is exploring a method called gonadal tissue cryopreservation (freezing and storing reproductive tissue) to help preserve fertility for individuals with certain disorders of sex development (DSD). These conditions can lead to a risk of cancer in the reproductive organs and/or infertility. For many, this experimental procedure is the only option to preserve their ability to have children. The study aims to see how well this method works (efficacy) and if it is safe. Researchers will look at how many tissue samples are viable and successfully frozen, and track any side effects. They will also ask patients and/or their guardians about their experience with this fertility preservation method.

Study design
This is an interventional study planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
Participants will undergo surgery to remove gonadal (reproductive) tissue as part of their standard medical care. A portion of this tissue will then be cryopreserved. Safety will be monitored for 72 hours after tissue removal, and acceptability will be assessed through surveys for up to ten years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety within 72 hours of tissue removal, and for acceptability through study completion, which could be up to ten years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06518746

Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation

Recruiting
NAUp to 30InterventionalPrevention
University of Colorado, Denver
~50 participants
Updated 2025-09-18 on ClinicalTrials.gov
What's tested:Cryopreservation of gonadal tissue

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy, as Assessed via the Proportion of total samples containing viable gonadal tissue and/or the presence of germ cells, and the Proportion of total samples that were successfully cryopreserved for the patient's future use.
Measured over Up to 48 hours after obtaining gonadal tissue samples.
+3 more outcomes measured
Ovarian Cancer
1 sites across 1 states
Colorado1
  • Kristine Corkum, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\< 30 years of age
Individuals diagnosed with a disorder of sex development who have any risk for malignancy in their gonadal tissue and will have their gonads removed for a clinical indication
Individuals diagnosed with a disorder of sex development who are at risk of primary ovarian insufficiency (POI) due to an underlying genetic condition

Exclusion

Pregnancy
Patients likely to retain inherent fertility and reproductive function
Patients deemed high risk for perioperative complications
Patients 7-17 years of age unable to provide assent (i.e. significant psychiatric problems/cognitive delay)
Patients 18 and older unable to provide consent (i.e. significant psychiatric problems/cognitive delay)
  • Efficacy, as Assessed via the Proportion of total samples containing viable gonadal tissue and/or the presence of germ cells, and the Proportion of total samples that were successfully cryopreserved for the patient's future use.Up to 48 hours after obtaining gonadal tissue samples.

    Determine the efficacy of gonadal tissue and germ cells cryopreservation for patients' future use to restore fertility and/or hormone function. Efficacy is defined as at least 30% of patients having viable gonadal tissue and/or germ cells present.

  • Safety, as Assessed via the Proportion of adverse eventswithin 72 hours of gonadal tissue removal

    Number and proportion of adverse events in gonadal tissue cryopreservation

  • Acceptability as a fertility preservation method, as Assessed via the survey responses by eligible patients and/or their guardians.Through study completion, up to ten years.

    Descriptive analysis of survey responses, including the Decision Regret Scale scores (mean/median scores across domains).

  • Level of demandThrough study completion, up to ten years.

    Descriptive analysis of the proportion of eligible patients who elect gonadal tissue cryopreservation (numerator) out of those who are eligible (denominator).